Observation On The Clinical Efficacy Of Chaishao Liujunzi Decoction Combined With Entecavir In The Treatment Of Chronic Hepatitis B Liver Fibrosis

Objective: By observing the non-invasive liver fibrosis model(FIB-4),serum indexes of liver fibrosis,liver function and liver stiffness value(LSM)of patients with liver-stagnation and spleen-deficiency chronic hepatitis B liver fibrosis treated with Chaishao Liujunzi combined with Entecavir The changes in the levels of these indicators to evaluate its clinical efficacy and safety provide a reference for the clinical application of Chaishao Liujunzi Decoction in the treatment of this disease.Methods: The cases were selected from the patients who were in Ruikang Hospital from February 2019 to February 2020,and 64 patients with chronic hepatitis B liver fibrosis of liver depression and spleen deficiency type that met the standard were randomly divided into treatment group and control group according to the random number table method.32 cases in the control group were given entecavir,and 32 cases in the treatment group were treated with Chaishao Liujunzi Decoction on the basis of the control group.The curative effect period of the two groups was 24 weeks.Observe and record the liver function(ALT,AST,GGT,TBIL)before and after treatment,the four items of liver fiber(HA,LN,PCIII,IV-C),liver stiffness value(LSM),FIB-4,abdominal ultrasound(portal vein diameter,Spleen thickness),TCM symptom scores and other index changes,use spss 25 for statistical analysis.Results: 1.Basic situation of enrollment: 64 patients were enrolled in this study.Among them,2 patients in the treatment group dropped off due to patients who stopped using traditional Chinese medicine and did not meet the treatment course.2 patients in the control group were lost to follow-up.Finally,60 patients were statistically analyzed.There was no significant difference between the two groups of patients in terms of gender,age,liver function,hepatic fibrosis,LSM,FIB-4,portal vein diameter,spleen thickness,TCM syndrome score and other indicators,and there was no significant difference(P>0.05),and they were comparable.2.Comparison of liver function indicators: After treatment,the ALT,AST,GGT and TBIL of the treatment group and the control group were significantly lower than those before the treatment(P<0.05);the liver function of the treatment group was significantly improved compared with the control group after the treatment P<0.05).3.Four comparisons of liver fiber: After the treatment,the HA,LN,PCIII,and IV-C of the treatment group and the control group were significantly lower than before treatment(P<0.05).After treatment,the HA,LN,PCIII,and PCIII of the treatment group IV-C was significantly lower than the control group(P<0.05).4.Comparison of LSM and FIB-4 between the two groups before and after treatment: After the treatment,the LSM and FIB-4 of the treatment group and the control group were lower than before the treatment(P<0.05);the LSM and FIB-4 of the treatment group after the treatment It was significantly lower than the control group(P<0.05).5.Comparison of portal vein diameter and spleen thickness between the two groups: After treatment,the portal vein diameter and spleen thickness of the treatment group and the control group were significantly smaller than before treatment(P<0.05);after treatment,the portal vein diameter and spleen thickness of the treatment group were compared with those of the control group The group shrank significantly(P<0.05).6.Comparison of HBV-DNA and HBe Ag negative conversion rate: After treatment,the HBV-DNA negative conversion rate and HBe Ag negative conversion rate of the treatment group and the control group were significantly higher than before the treatment(P<0.05);after the treatment,the treatment group and the control group In comparison,there was no significant statistical difference(P>0.05). 7.Comparison of overall efficacy of traditional Chinese medicine: After the treatment,the total effective rate of the treatment group is 86.67%,and the total effective rate of the control group is 66.67%.The treatment group is better than the control group(P<0.05).8.Comparison of TCM syndrome scores: After treatment,the TCM syndrome scores and total scores of the two groups were significantly lower than those before treatment(P<0.05).After treatment,the TCM syndrome scores and total scores of the treatment group were compared with those of the control group Significantly decreased(P<0.05).Conclusion:1.Chaishao Liujunzi Decoction combined with Entecavir has a significant clinical effect in the treatment of patients with chronic hepatitis B liver fibrosis.It can improve liver function(AST,ALT,TBIL,GGT),liver fibrosis indicators(HA,PCⅢ,Ⅳ-C,LN).),LSM and FIB-4,reducing the inner diameter of the portal vein and the thickness of the spleen are better than the simple entecavir group.2.In terms of the comprehensive curative effect of traditional Chinese medicine,the combination of Chaishao Liujunzi Decoction and Entecavir in the treatment of patients with chronic hepatitis B hepatic fibrosis has obvious advantages in improving clinical symptoms and reducing TCM syndrome scores.Traditional Chinese and Western medicine treatment can effectively improve the therapeutic effect.